Date published: 2026-5-12

1-800-457-3801

SCBT Portrait Logo
Seach Input

CC10 Inhibitors

CC10, also known as Secretoglobin Family 1A Member 1 (SCGB1A1) or Clara Cell Secretory Protein (CCSP), is a small secretory protein predominantly produced by Clara cells in the respiratory bronchioles. This protein has garnered interest due to its multifaceted roles in the pulmonary system. Serving as an anti-inflammatory modulator, CC10 acts to mitigate immune responses within the respiratory tract and offers protection against oxidative damage. It achieves this through several mechanisms, including the inhibition of phospholipase A2 activity, which in turn hinders certain inflammatory processes. Additionally, CC10 has the ability to bind and neutralize various inflammatory mediators, emphasizing its significance in preserving the balance and health of the respiratory system. Given its central role in lung protection and immune modulation, elucidating the functions and regulatory mechanisms of CC10 is pivotal for a comprehensive understanding of respiratory biology. CC10 (SCGB1A1) inhibitors are a class of chemical entities tailored to specifically target and modulate the activity or expression of CC10. The action of these inhibitors spans a range of mechanisms. Some compounds might bind directly to CC10, obstructing its interaction with other molecular targets or its ability to be secreted, thereby influencing its overall functional profile. Others might intervene in the synthesis, post-translational processing, or secretion pathways of CC10, altering its concentrations in lung tissues or respiratory secretions. Yet, some inhibitors might exert their effects at the genetic or transcriptional level, modulating the expression dynamics of the SCGB1A1 gene.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Dexamethasone

50-02-2sc-29059
sc-29059B
sc-29059A
100 mg
1 g
5 g
$91.00
$139.00
$374.00
36
(1)

Dexamethasone, a synthetic glucocorticoid, can suppress CC10 expression through its interaction with the glucocorticoid receptor.

Mifepristone

84371-65-3sc-203134
100 mg
$61.00
17
(1)

Mifepristone is a glucocorticoid receptor antagonist that can counteract the upregulation of CC10 by glucocorticoids, thereby reducing its expression.

Tamoxifen

10540-29-1sc-208414
2.5 g
$272.00
18
(2)

Tamoxifen, a selective estrogen receptor modulator, can alter estrogen signaling and has been shown to reduce CC10 expression.

ICI 182,780

129453-61-8sc-203435
sc-203435A
1 mg
10 mg
$83.00
$187.00
34
(1)

ICI 182,780 is an estrogen receptor antagonist that can suppress CC10 expression by blocking estrogen signaling.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD98059 is a MAPK/ERK inhibitor. Since the MAPK/ERK pathway can regulate CC10, inhibiting it can down-regulate CC10 expression.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin is a PI3K inhibitor. PI3K signaling is involved in CC10 regulation, so its inhibition can reduce CC10 levels.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 is another PI3K inhibitor, which can reduce CC10 expression by inhibiting the PI3K pathway.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB203580 is a p38 MAPK inhibitor. p38 MAPK can regulate CC10, and its inhibition may lead to reduced CC10 expression.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is a JNK inhibitor. JNK pathways can influence CC10 expression, and its inhibition can down-regulate the protein.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$64.00
$246.00
136
(2)

U0126 is a MEK1/2 inhibitor that can affect the MAPK/ERK pathway and thus can reduce CC10 expression.